Latest Clinical Trials News

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

4DMedical reports a remarkable 202% increase in Q2 FY2025 operating revenue, driven by rapid site expansion and key collaborations with leading healthcare providers and the U.S. Department of Defense.

Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

Opthea Limited has spotlighted Sozinibercept as a potential game-changer in wet age-related macular degeneration (AMD) therapy, presenting compelling clinical data and a clear path to U.S. market entry.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

Resonance Health has reported record quarterly customer receipts of $5 million, a 57% increase from the previous quarter, alongside a major $13.8 million clinical trial contract win, signaling robust growth across its healthcare technology and clinical trial services.

Clarity Pharmaceuticals will present compelling data on its 64Cu-SAR-bisPSMA diagnostic agent at two leading oncology conferences, highlighting earlier and more accurate prostate cancer lesion detection than current standards.

EMVision Medical Devices reports strong progress in clinical trials for its emu™ Bedside Scanner, backed by robust cash reserves and strategic non-dilutive funding. The company is poised to commence pivotal FDA validation trials, marking a key step toward commercialisation.